ad image

Regeneron

1 / 1
Regeneron
Expansion

Governor Cuomo Announces Regeneron's $1.8 Billion Expansion in Westchester County

Regeneron

PR-M07-21-013-843Jul 23, 2021
Regeneron
COVID

Regeneron Phase III Trial Shows 81% Reduced Risk of COVID

Regeneron

PR-M04-21-014Apr 16, 2021
BioNTech
Collaboration

BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo Combination in Melanoma

BioNTech

PR-M08-20-NI-06Jul 31, 2020
Regeneron Expands Partnership with RNAi Drug Developer Alnylam
Partnership

Regeneron Expands Partnership with RNAi Drug Developer Alnylam

Emilie Branch

Pharma's Almanac

PAO-M04-19-NI-013Apr 10, 2019
Sanofi
Patent

Regeneron and Sanofi Strongly Disagree with Verdict Upholding Three of Five Amgen U.S. Patent Claims Relating to PCSK9 Antibodies

Sanofi

PR-M02-19-NI-059Feb 26, 2019
Sanofi
Immuno-oncology

Regeneron and Sanofi Restructure Immuno-Oncology Collaboration for Discovery and Development Programs

Sanofi

PR-M01-19-NI-031Jan 10, 2019
Sanofi and Regeneron Immuno-oncology Collaboration Ending
Immuno-oncology

Sanofi and Regeneron Immuno-oncology Collaboration Ending

Nice Insight

PAO-M01-19-NI-012Jan 09, 2019
Regeneron
FDA Approval

FDA Approves Asthma Indication for Dupixent® (dupilumab)

Regeneron

PR-M10-18-NI-090Oct 25, 2018
Teva Pharmaceutical Industries
Study Results

Regeneron and Teva Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip

Teva Pharmaceutical Industries

PR-M09-18-NI-059Sep 20, 2018
Regeneron
Regulatory

Regeneron Provides Regulatory Update on EYLEA® (aflibercept) Injection sBLA in Wet Age-Related Macular Degeneration

Regeneron

PR-M09-18-NI-016Sep 07, 2018
Regeneron
Collaboration

Regeneron and bluebird bio Announce Collaboration to Discover, Develop and Commercialize New Cell Therapies for Cancer

Regeneron

PR-M08-18-NI-054Aug 14, 2018
1 / 1